Charles Perou, PhD (IMAGE)
Caption
“We know that breast cancers have molecularly distinct features with differing biological bases and outcomes. In that regard, we need biomarker tools to guide treatment escalation and de-escalation for many types of breast cancer, in particular, HER2-positive and triple-negative breast cancers, which can be difficult to treat. Some of our previous studies have already shown the prognostic and predictive ability of B cell-related signatures in triple-negative breast cancers. It would not surprise us if a similar analysis in triple-negative breast cancer found the same results as those in this current study of HER2-positive cancers.”
Credit
UNC Lineberger Comprehensive Cancer Center
Usage Restrictions
None
License
Original content